NDAORALSYRUP
Approved
Apr 1951
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
BENTYL (dicyclomine hydrochloride) by Teva is tract. Approved for functional bowel/irritable bowel syndrome (). First approved in 1951.
Drug data last refreshed 12h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BENTYL (dicyclomine hydrochloride) is an oral anticholinergic agent approved in 1951 for functional bowel disorder and irritable bowel syndrome. It works via dual mechanism: antimuscarinic effects at acetylcholine receptors (~1/8 potency of atropine) and direct smooth muscle relaxation (musculotropic action). The drug reduces intestinal spasms by antagonizing both cholinergic and non-cholinergic agonists.
$0.051MPart D
LOE ApproachingDeclining
Mature product with minimal growth trajectory; expect defensive positioning and cost-optimization focus rather than expansion initiatives.
Mechanism of Action
tract. Animal studies indicate that this action is achieved via a dual mechanism: a specific anticholinergic effect (antimuscarinic) at the acetylcholine-receptor sites with approximately 1/8 the milligram potency of atropine ( in vitro , guinea pig ileum); and a direct effect upon smooth muscle…
Indications (1)
Worked on BENTYL at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.